Smiths Detection Hold Baggage Screening Technology to Support Upgrade to ECAC Standard 3 EDS at Munich Airport
10.10.2017 11:00:00 EEST | Business Wire | Press release
Smiths Detection has been selected by the District Government of Upper Bavaria to supply ECAC Standard 3 EDS hold baggage screening systems to Munich Airport. The contract comprises 25 x HI-SCAN 10080 XCT advanced scanners which amalgamate high resolution X-ray technology, computed tomography (CT) and advanced detection algorithms to deliver exceptional levels of security whilst also increasing operational efficiency. A service agreement is also included.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171010005842/en/
HI-SCAN 10080 XCT advanced hold baggage scanners (Photo: Business Wire)
The scanners will not only detect the explosives threats specified by the new standard, but can also be easily upgraded to meet future requirements to identify evolving threats. Combining a very fast belt speed with a large rectangular tunnel, they offer a continuously high throughput of up to 1,800 bags per hour. Extremely sharp, full colour, high resolution images, as well as a low false alarm rate also support the greater levels of efficiency required by the new regulations.
Munich is Germany’s second largest airport and the only one in Europe to be awarded 5-star status in the Skytrax World Airport Rating. It already handles 100 airlines flying to over 250 destinations in over 70 countries with plans for further development. The new technology will deliver the efficiencies required by such a busy hub both now and in the future.
“We welcome the opportunity to help airports in upgrading to ECAC Standard 3. It is a major step but the rewards are significant in terms of higher levels of security and operational efficiency,” explained Tony Tielen, VP EMEA for Smiths Detection. “The new equipment will be seamlessly integrated into Munich Airport’s existing infrastructure to ensure smooth ongoing service during the upgrade.”
To be deployed in both terminals, the first three scanners will be installed and fully operational by the end of this year. The remaining installations will be progressively rolled out between 2018 and 2021. Also included in the deal are 49 Level 2 and 3 workstations and a Matrix Server.
Ends
Notes to editors
HI-SCAN 10080 XCT key features:
- EU/ECAC EDS Standard 3 approved
- Laboratory certified for high-speed checked baggage screening by the United States Transportation Security Administration (TSA)
- Belt speed of 0.5m/sec (98.5ft/min)
- High throughput of up to 1800 bags per hour
- Large tunnel capable of screening objects 100 x 80 cm (39.4 x 31.5in)
A dual-energy X-ray line scanner with full 3D volumetric Computed Tomography (CT) imaging and reconstruction, the HI-SCAN 10080 XCT is the next generation high-speed checked baggage explosives detection system (EDS).
With a belt speed of 0.5m/sec (98.5ft/min) and a large 1070 x 810mm (42.1 x 31.9in) rectangular tunnel, the HI-SCAN 10080 XCT provides the most economical solution for airport checked baggage screening requirements. This combination of belt speed and tunnel size will provide baggage handling systems the capability to process a throughput of up to 1800 bags/hour with object sizes of up to 1000 x 800 mm (39.4 x 31.5in).
The HI-SCAN 10080 XCT is designed to integrate easily into newly implemented Hold Baggage System (HBS) configurations or as a replacement for current baggage handling systems.
Further details on the Smiths Detection HI-SCAN 10080 XCT can be found here: http://www.smithsdetection.com/index.php?option=com_k2&view=item&id=157:hi-scan-10080-xct&Itemid=101&lang=en#.WKwoEoXXLmg
About Smiths Detection
Smiths Detection, part of Smiths Group, is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and military markets. With more than 40 years of field-tested experience, we deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.
Our goal is simple – to provide security, peace of mind and freedom of movement upon which the world depends. For more information visit www.smithsdetection.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171010005842/en/
Contact information
Smiths Detection
Media relations:
Karen Kulinski
Global
Aviation Marketing Director
+49 (0)611 9412 422
karen.kulinski@smithsdetection.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom